How did CERO's expenses impact its profitability in Q3 2024?

CERO's expenses had a significant impact on its profitability in Q3 2024, with the company reporting a net loss of approximately $2.86 million for the period.

1. **R&D Expenses**: The company's research and development (R&D) expenses were $2.63 million, which is a substantial portion of the total expenses and directly impacts the net income. R&D costs are critical for biotech companies like CERO, as they invest heavily in developing new therapies and products.
2. **Selling, General, and Administrative Expenses**: The selling, general, and administrative (SG&A) expenses were not provided separately, but they are also a significant expense category for companies, especially those in the biotech sector. These expenses include costs related to sales, marketing, and administrative functions, which can be substantial as companies build their commercial infrastructure and market their products.
3. **Net Income**: The net income for the period was $1.77 million, which indicates that while the company had a positive income, it was not enough to cover all the expenses, resulting in a net loss. This net income was likely impacted by the R&D expenses, which are crucial for the company's long-term goals but do not generate immediate revenue.

In conclusion, CERO's R&D expenses, along with possibly SG&A expenses, had a significant negative impact on its profitability in Q3 2024, leading to a net loss despite a positive net income. These expenses are essential for the company's future prospects but require careful management to ensure sustainable financial health.